


Supplemental figure legend:

Effect of cycloleucine, SAM or MTA treatment on luciferase activity driven by the human BHMT promoter (**part A**) and cellular SAM levels (**part B**). HepG2 cells transfected transiently with the BHMT promoter construct -347/+33-LUC and treated with cycloleucine (20mM, 2 hr pretreatment) or vehicle control followed by SAM (5mM for 12 hrs) or MTA (1mM for 12 hrs) or vehicle control. Cycloleucine was added back with either SAM or MTA. Cells were co-transfected with Renilla luciferase for control of transfection efficiency. Some cells were processed for SAM level determination as described in Methods. Results represent mean \pm SEM from three (SAM levels) to six (promoter activity) independent experiments performed in triplicates. Promoter activity data is expressed as relative luciferase activity to that of pGL-3 basic vector control, which is assigned a value of 1.0. Cellular SAM levels are expressed as nmol/mg protein. For part A, *p<0.005 versus control, †p<0.05 versus control and SAM treatment. For part B, *p<0.05 versus control, †p<0.05 vs. MTA.

A.**B.**